Anti-hypertensive agents inhibit in vivo the formation of advanced glycation end products and improve renal damage in a type 2 diabetic nephropathy rat model

Journal of the American Society of Nephrology

Volumn 14, Issue 5, 2003, Pages 1212-1222

  Nangaku, Masaomi ^a   Miyata, Toshio ^b   Sada, Toshio ^c   Mizuno, Makoto ^c   Inagi, Reiko ^b   Ueda, Yasuhiko ^b   Ishikawa, Naoyoshi ^b   Yuzawa, Hiroko ^b   Koike, Hiroyuki ^c   Van Ypersele De Strihou, Charles ^d   Kurokawa, Kiyoshi ^b  

^a UNIVERSITY OF TOKYO   (Japan)

^b TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c Molec Biology Research Laboratory   (Japan)

^d UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE; HYDRALAZINE; INSULIN; OLMESARTAN; PENTOSIDINE;

AEROBIC METABOLISM; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIABETIC NEPHROPATHY; DOSE RESPONSE; DRUG EFFECT; GLUCOSE BLOOD LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HISTOPATHOLOGY; HYPERTENSION; IMMUNOHISTOCHEMISTRY; INSULIN BLOOD LEVEL; KIDNEY FUNCTION; KIDNEY INJURY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SPONTANEOUSLY HYPERTENSIVE RAT; STATISTICAL SIGNIFICANCE;

EID: 0037407792     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ASN.0000062961.76776.C1     Document Type: Article

References (27)

1. Remuzzi G, Schieppati A, Ruggenenti P: Nephropathy in patients with type 2 diabetes. N Engl J Med 346: 1145-1151, 2002
2. Ritz E, Orth SR: Nephropathy in patients with type 2 diabetes mellitus. N Engl J Med 341: 1127-1133, 1999
3. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I: Collaborative Study Group: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345: 851-860, 2002
4. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S: RENAAL Study Investigators: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345: 861-869, 2002
5. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Amer P: Irbesartan in PATIENTS with Type 2 Diabetes and Microalbuminuria Study Group: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345: 870-878, 2002
6. Patrick DH, Hansen CT, Canary JJ, Wemer RM, Carswell N: Insulin-independent diabetes mellitus (type II) spontaneous hypertensive/NIH corpulent rat. Am J Pathol 123: 398-400, 1986
7. Miyata T, van Ypersele de Strihou C, Ueda Y, Ichimori K, Inagi R, Onogi H, Ishikawa N, Nangaku M, Kurokawa K: Angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors lower in vitro the formation of advanced glycation end products: Biochemical mechanisms. J Am Soc Nephrol, 13: 2478-2487, 2002
8. Uehara Y, Hirawa N, Kawabata Y, Suzuki T, Ohshima N, Oka K, Ikeda T, Goto A, Toyo-oka T, Kizuki K: Long-term infusion of kallikrein attenuates renal injury in Dahl salt-sensitive rats. Hypertension 24: 770-778, 1994
9. Horie K, Miyata T, Yasuda T, Takeda A, Yasuda Y, Maeda K, Sobue G, Kurokawa K: Immunohistochemical localization of advanced glycation end products, pentosidine, and carboxymethyllysine in lipofuscin pigments of Alzheimer's disease and aged neurons. Biochem Biophys Res Commun 236: 327-332, 1997
10. Miyata T, Ishikawa S, Asahi K, Inagi R, Suzuki D, Horie K, Tatsumi K, Kurokawa K: 2-Isopropylidenehydrazono-4-oxothiazolidin-5ylacetanilide (OPB-9195) inhibits the neointima proliferation of rat carotid artery following balloon injury: Role of glycoxidation and lipoxidation reactions in vascular tissue damage. FEBS Lett 445: 202-206, 1999
11. Miyata T, Taneda S, Kawai R, Ueda Y, Horiuchi S, Hara M, Maeda K, Monnier VM: Identification of pentosidine as a native structure for advanced glycation end products in β2-microglobulin-containing amyloid fibrils in patients with dialysis-related amyloidosis. Proc Natl Acad Sci 93: 2353-2358, 1996
12. Hostetter TH: Prevention of end-stage renal disease due to type 2 diabetes. N Engl J Med 345: 910-912, 2001
13. Nagao T, Yamaguchi I, Narita H, Nakajima H: Calcium entry blockers: Antihypertensive and natriuretic effects in experimental animals. Am J Cardiol 56: 56H-61H, 1985
14. Zak SB, Lukas G, Gilleran TG: Plasma levels of real and "apparent" hydralazine in man and rat. Drug Metab Dispos 5: 116-121, 1977
15. Forbes JM, Cooper ME, Thallas V, Bums WC, Thomas MC, Brammar GC, Lee F, Grant SL, Burrell LA, Jerums G, Osicka TM: Reduction of the accumulation of advanced glycation end products by ACE inhibition in experimental diabetic nephropathy. Diabetes 51: 3274-3282, 2002
16. Wilkinson-Berka JL, Kelly DJ, Koerner SM, Jaworski K, Davis B, Thallas V, Cooper ME: ALT-946 and aminoguanidine, inhibitors of advanced glycation, improve severe nephropathy in the diabetic transgenic (mREN-2)27 rat: Diabetes 51: 3283-3289, 2002
17. Soulis-Liparota T, Cooper M, Papazoglou D, Clarke B, Jerums G: Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozocin-induced diabetic rat. Diabetes 40: 1328-1334
18. Nakamura S, Makita Z, Ishikawa S, Yasumura K, Fujii W, Yanagisawa K, Kawata T, Koike T: Progression of nephropathy in spontaneous diabetic rats is prevented by OPB-9195, a novel inhibitor of advanced glycation. Diabetes 46: 895-899, 1997
19. Degenhardt TP, Alderson NL, Arrington DD, Beattie RJ, Basgen JM, Steffes MW, Thorpe SR, Baynes JW: Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat. Kidney Int 61: 939-950, 2002
20. Zoja C, Coma D, Rottoli D, Cattaneo D, Zanchi C, Tomasoni S, Abbate M, Remuzzi G: Effect of combining ACE inhibitor and statin in severe experimental nephropathy. Kidney Int 61: 1635-1645, 2002
21. Bucala R, Makita Z, Vega G, Grundy S, Koschinsky T, Cerami A, Vlassara H: Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency. Proc Natl Acad Sci 61: 9441-9445, 1994
22. Fishbane S, Bucala R, Pereira BJ, Founds H, Vlassara H: Reduction of plasma apolipoprotein-B by effective removal of circulating glycation derivatives in uremia. Kidney Int 52: 1645-1650, 1997
23. Sugiyama S, Miyata T, Ueda Y, Tanaka H, Maeda K, Kawashima S, Van Ypersele de Strihou C, Kurokawa K: Plasma levels of pentosidine in diabetic patients: an advanced glycation end product. J Am Soc Nephrol 9: 1681-1688, 1998
24. Miyata T, van Ypersele de Strihou C, Kurokawa K, Baynes JW: Alterations in nonenzymatic biochemistry in uremia: origin and significance of "carbonyl stress" in long-term uremic complications. Kidney Int 55: 389-399, 1999
25. Miyata T, Kurokawa K, Charles van Ypersele de Strihou. Advanced glycation and lipoxidation end products: Role of reactive carbonyl compounds generated during carbohydrate and lipid metabolism. J Am Soc Nephrol 11: 1744-1752, 2000
26. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators: Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 355: 253-259, 2000
27. Parving HH, Hommel E, Jensen BR, Hansen HP: Long-term beneficial effect of ACE inhibition on diabetic nephropathy in normotensive type 1 diabetic patients. Kidney Int 60: 228-234, 2001